These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10500807)

  • 1. Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Adv Exp Med Biol; 1999; 457():313-24. PubMed ID: 10500807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
    Chiodini B; Bassan R; Barbui T
    Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line.
    Hu XF; Slater A; Rischin D; Kantharidis P; Parkin JD; Zalcberg J
    Br J Cancer; 1999 Feb; 79(5-6):831-7. PubMed ID: 10070877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
    Lotfi K; Zackrisson AL; Peterson C
    Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
    Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
    Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
    Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
    Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
    Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line.
    Hu XF; Slater A; Wall DM; Kantharidis P; Parkin JD; Cowman A; Zalcberg JR
    Br J Cancer; 1995 May; 71(5):931-6. PubMed ID: 7734315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.
    Biscardi M; Caporale R; Pagliai G; Leoni F; Bernabei P; Santini V; Ciolli S; Grossi A
    Leuk Res; 2003 Dec; 27(12):1125-34. PubMed ID: 12921951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
    Mülder HS; Dekker H; Pinedo HM; Lankelma J
    Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
    Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
    Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results.
    Bassan R; Chiodini B; Zucchetti M; Lerede T; Cornelli PE; Cortelazzo S; Barbui T
    Haematologica; 1998 Jan; 83(1):27-33. PubMed ID: 9542320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
    Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
    Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
    Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
    Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
    Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
    Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of uptake mechanisms for anthracyclines in human leukemic cells.
    Karim H; Bogason A; Bhuiyan H; Fotoohi AK; Lafolie P; Vitols S
    Curr Drug Deliv; 2013 Aug; 10(4):404-12. PubMed ID: 23062181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
    Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
    Cancer Chemother Pharmacol; 1996; 39(1-2):157-61. PubMed ID: 8995514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric evaluation of fas expression in relation to response and resistance to anthracyclines in leukemic cells.
    Labroille G; Dumain P; Lacombe F; Belloc F
    Cytometry; 2000 Mar; 39(3):195-202. PubMed ID: 10685076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
    Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
    Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.